BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...six products in Phase I or I/II trials and the rest in discovery or preclinical development.Vaxart Inc....
BioCentury | Feb 4, 2021
Product Development

Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

...By Sandi Wong, Assistant Editor Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase...
...Drugs Controller General of India (DCGI) in January. Sandi Wong Oral tablet COVID-19 vaccine (VXA-CoV2-1) Gam-COVID-Vac Lyo NVX-CoV2373 Covaxin (BBV152) CoronaVac, PiCoVacc Vaxart Inc. The...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...with high short interestA FactSet analysis named Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Inovio Pharmaceuticals Inc. (NASDAQ:INO), Vaxart Inc....
BioCentury | Nov 7, 2020
Translation in Brief

Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more

...to the hapten dinitrophenyl, against which most humans naturally express antibodies, to stimulate antiviral immune responses. Vaxart Inc....
...A and B infection.TARGETSACE2 – Angiotensin-converting enzyme 2 Danielle Golovin Relenza, zanamivir (GG167) Neoleukin Therapeutics Inc. University of Lausanne Purdue University Vaxart Inc. Angiotensin-converting...
BioCentury | Sep 9, 2020
Product Development

COVID-19 roundup: SpyBiotech-Serum Institute of India send HBV-based COVID-19 vaccine to clinic; plus Vaxart, Inovio-Thermo Fisher and RedHill

...links the SARS-CoV-2 spike protein to the surface of a hepatitis B surface antigen (HBsAg) VLP.Vaxart’s...
...U.S. Phase II/III trial in an outpatient setting this year.TARGETSSPHK2 – Sphingosine kinase 2 BC Staff SpyBiotech Ltd. Vaxart Inc. Inovio...
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

...Bourla, chairman and CEO of Pfizer, said Friday. Pfizer’s news came the same day that Vaxart Inc....
...Bourla said, but “during the pandemic we will try to provide discounts.” Warp Speed vetting Vaxart...
...COVID-19 vaccine doses by January (see “Trump Administration Lays Out Path” ). The efficacy of Vaxart’s...
BioCentury | Jun 5, 2020
Product Development

Emergent playing key role in manufacturing COVID-19 vaccines via PPP set up for flu

...NYSE:JNJ), a protein-based vaccine from Novavax Inc. (NASDAQ:NVAX) and a protein-based oral vaccine candidate from Vaxart Inc....
...million from J&J, which is receiving U.S. government funding, and undisclosed funding from Novavax and Vaxart...
BioCentury | Jun 2, 2020
Product Development

CDMO Emergent, partner to three COVID-19 vaccine developers, gets $628M BARDA task order

...partner to three developers of vaccine candidates: Johnson & Johnson (NYSE:JNJ), Novavax Inc. (NASDAQ:NVAX) and Vaxart Inc....
...coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Paul Bonanos, Associate Editor Emergent BioSolutions Inc. Johnson & Johnson Novavax Inc. Vaxart Inc. COVID-19 cov19count cov19count...
BioCentury | May 22, 2020
Product Development

Monkey rechallenge data provide COVID-19 neutralizing antibody benchmark for vaccine developers

...As IMV and Vaxart prepare to advance their COVID-19 vaccine candidates into the clinic, monkey data...
...lower clinical scores after rechallenge compared with primary infection. Separately, IMV Inc. (TSX:IMV; NASDAQ:IMV) and Vaxart Inc....
...of DPX-COVID-19, which comprises multiple peptide antigens formulated within its DPX platform for lipid-based delivery. Vaxart...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

...a San Francisco Bay Area-based research partnership founded by Jennifer Doudna. Viral vaccines queuing up Vaxart Inc....
...five oral COVID-19 vaccine candidates in preclinical testing to pick its clinical candidate. Each of Vaxart’s...
...the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Qiagen N.V. Becton Dickinson and Co. Vaxart Inc. Cobra...
Items per page:
1 - 10 of 47
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...six products in Phase I or I/II trials and the rest in discovery or preclinical development.Vaxart Inc....
BioCentury | Feb 4, 2021
Product Development

Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

...By Sandi Wong, Assistant Editor Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase...
...Drugs Controller General of India (DCGI) in January. Sandi Wong Oral tablet COVID-19 vaccine (VXA-CoV2-1) Gam-COVID-Vac Lyo NVX-CoV2373 Covaxin (BBV152) CoronaVac, PiCoVacc Vaxart Inc. The...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...with high short interestA FactSet analysis named Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Inovio Pharmaceuticals Inc. (NASDAQ:INO), Vaxart Inc....
BioCentury | Nov 7, 2020
Translation in Brief

Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more

...to the hapten dinitrophenyl, against which most humans naturally express antibodies, to stimulate antiviral immune responses. Vaxart Inc....
...A and B infection.TARGETSACE2 – Angiotensin-converting enzyme 2 Danielle Golovin Relenza, zanamivir (GG167) Neoleukin Therapeutics Inc. University of Lausanne Purdue University Vaxart Inc. Angiotensin-converting...
BioCentury | Sep 9, 2020
Product Development

COVID-19 roundup: SpyBiotech-Serum Institute of India send HBV-based COVID-19 vaccine to clinic; plus Vaxart, Inovio-Thermo Fisher and RedHill

...links the SARS-CoV-2 spike protein to the surface of a hepatitis B surface antigen (HBsAg) VLP.Vaxart’s...
...U.S. Phase II/III trial in an outpatient setting this year.TARGETSSPHK2 – Sphingosine kinase 2 BC Staff SpyBiotech Ltd. Vaxart Inc. Inovio...
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

...Bourla, chairman and CEO of Pfizer, said Friday. Pfizer’s news came the same day that Vaxart Inc....
...Bourla said, but “during the pandemic we will try to provide discounts.” Warp Speed vetting Vaxart...
...COVID-19 vaccine doses by January (see “Trump Administration Lays Out Path” ). The efficacy of Vaxart’s...
BioCentury | Jun 5, 2020
Product Development

Emergent playing key role in manufacturing COVID-19 vaccines via PPP set up for flu

...NYSE:JNJ), a protein-based vaccine from Novavax Inc. (NASDAQ:NVAX) and a protein-based oral vaccine candidate from Vaxart Inc....
...million from J&J, which is receiving U.S. government funding, and undisclosed funding from Novavax and Vaxart...
BioCentury | Jun 2, 2020
Product Development

CDMO Emergent, partner to three COVID-19 vaccine developers, gets $628M BARDA task order

...partner to three developers of vaccine candidates: Johnson & Johnson (NYSE:JNJ), Novavax Inc. (NASDAQ:NVAX) and Vaxart Inc....
...coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Paul Bonanos, Associate Editor Emergent BioSolutions Inc. Johnson & Johnson Novavax Inc. Vaxart Inc. COVID-19 cov19count cov19count...
BioCentury | May 22, 2020
Product Development

Monkey rechallenge data provide COVID-19 neutralizing antibody benchmark for vaccine developers

...As IMV and Vaxart prepare to advance their COVID-19 vaccine candidates into the clinic, monkey data...
...lower clinical scores after rechallenge compared with primary infection. Separately, IMV Inc. (TSX:IMV; NASDAQ:IMV) and Vaxart Inc....
...of DPX-COVID-19, which comprises multiple peptide antigens formulated within its DPX platform for lipid-based delivery. Vaxart...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

...a San Francisco Bay Area-based research partnership founded by Jennifer Doudna. Viral vaccines queuing up Vaxart Inc....
...five oral COVID-19 vaccine candidates in preclinical testing to pick its clinical candidate. Each of Vaxart’s...
...the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Qiagen N.V. Becton Dickinson and Co. Vaxart Inc. Cobra...
Items per page:
1 - 10 of 47